Prospects and Problems in Synthetic Vaccine Development: What did We Learn from the Cholera Toxin System?

  • Chaim O. Jacob


The cholera toxin is a 84-kilodalton protein composed of two noncovalently bound subunits, A and B. The A subunit is the proenzyme form of an ADP-ribosyltransferase that is responsible for the biological activity of the toxin through its ability to activate target cell adenylate cyclase. The B subunit is the immunologically dominant region consisting of five identical, noncovalently associated B chains composed of 103 amino acids that are responsible for binding the toxin to target cell membrane receptors containing the oligosaccharide of the GM1 ganglioside. Neutralizing antibodies raised against the holotoxin react mainly with the B subunit, and antibodies against the B subunit are capable of neutralizing the biological activity of the intact toxin.


Synthetic Peptide Cholera Toxin Tetanus Toxoid Cyanogen Bromide Parent Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Audibert, F., Jolivet, M., Chedid, L., Arnon, R., and Sela, M. (1982), Successful immunization with a totally synthetic diphteria vaccine, Proc. Natl. Acad. Sci. U.S.A. 79:5042–5046.PubMedCrossRefGoogle Scholar
  2. Bavoil, P., Newton, S., Stocker, B. A., D., and Jacob, C. O. (unpublished data).Google Scholar
  3. Charbit, A., Boulain, J. C., Ryter, A., and Hofnung, M. (1986), Probing the topology of a bacterial membrane protein by genetic insertion of a foreign epitope ; expression at the ell surface, EMBO J. 5:3029–3039.PubMedGoogle Scholar
  4. DeWolf, M. J. S., Fridkin, M., Epstein, M., and Kohn, L. D. (1981), Structure-function studies of cholera toxin and its A and B promoters ; modification of tryptophan residues, J. Biol. Chem. 256:5481–5488.Google Scholar
  5. Duffy, L. K. and Lai, C. Y. (1979), Involvement of arginine residues in the binding site of cholera toxin subunit B, Biochem. Biophys. Res. Commun. 91:1005–1010.PubMedCrossRefGoogle Scholar
  6. Finkelstein, R. A., Burks, M. F., Zupan, A., Dallas, W. S., Jacob, C. O., and Ludwig, D. S. (1987), Antigenic determinants of the cholera/coli family of enterotoxins, Rev. Infect. Dis. 9:S490-S502.CrossRefGoogle Scholar
  7. Herzenberg, L. A., Tokuhira, T., and Herzenberg, L. H. (1980), Carrier-priming leads to hapten-specific suppression, Nature 285:664–667.PubMedCrossRefGoogle Scholar
  8. Hopp, T. P. (1984), Immunogenicity of a synthetic HBsAg peptide:Enhancement by conjuation to a fatty acid carrier, Mol. Immunol. 21:13–16.PubMedCrossRefGoogle Scholar
  9. Jacob, C. O., Harari, I., Arnon, R., and Sela, M. (1986), Antibodies to cholera toxin synthetic peptides of increasing size and their reactivity with related toxins, Vaccine 4:9–98.CrossRefGoogle Scholar
  10. Jacob, C. O., Pimes, M., and Arnon, R. (1984), Neutralization of heat-labile toxin of E. coli by antibodies to synthetic peptides derived from B subunit of cholera toxin, EMBO J. 3:2889–2893.PubMedGoogle Scholar
  11. Jacob, C. O., Arnon, R., and Sela, M. (1985), Effect of carrier on the immunogenic capacity of synthetic cholera vaccine, Mol. Immunol. 22:1333–1339.PubMedCrossRefGoogle Scholar
  12. Jacob, C. O., Arnon, R., and Sela, M. (1986), Anti-cholera response elicited in aqueous solution by a completely synthetic antigen with built- in adjuvanticity, Immunol. Letters 14:43–48.CrossRefGoogle Scholar
  13. Jacob, C. O., Sela, M., Pimes, M., Hurwitz, S., and Arnon, R. (1984), Both cholera toxin- induced adenylate cyclase activation and cholera toxin induced biological activity are inhibited by antibodies against related synthetic peptides, Proc. Natl. Acad. Sci. U. S.A. 81:7893–7896.PubMedCrossRefGoogle Scholar
  14. Jacob, C. O., Leitner, M., Zamir, A., Salomon, D., and Arnon, R. (1985), Priming immunization against cholera toxin and E. coli heat-labile toxin by a cholera toxin short peptide- β-galactosidase hybrid synthesized in E. coli, EMBO J. 4:3339–3343.PubMedGoogle Scholar
  15. Newton, S. M. C., Jacob, C. O., and Stocker, B. A. D. ( (1989), Immune response to cholera toxin epitope inserted in Salmonella flagellin, Science (in press).Google Scholar
  16. Sela, M., and Arnon, R.(1960), Studies on the chemical basis of the antigenicity of proteins. The role of rigidity in the antigenicity of polypeptidyl gelatins, Biochem. J. 77:394–399.PubMedGoogle Scholar
  17. Shapira, M., personal communication.Google Scholar
  18. Siddiqui, W. A., Kan, S. C., Kramer, K., Case, S., Palmer, K. (1981), Use of a synthetic adjuvant in an effective vaccination of monkeys against malaria, Nature 289:64–66.PubMedCrossRefGoogle Scholar
  19. Skehel, J. J., and Ada, G. L. (1985), Are peptides good antigens? Nature 316:764–765.PubMedCrossRefGoogle Scholar
  20. Westhof, E., Altschuk, D., Moras, D., Bloomer, A. C., Mondragon, A., Klug, A., and Van Regenmortel, M. H. V. (1984), Correlation between segmental mobility and the location of antigenic determinants in proteins, Nature 311:123–126.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Chaim O. Jacob
    • 1
  1. 1.Department of Microbiology and ImmunologyStanford University School of MedicineStanfordUSA

Personalised recommendations